Trial · NCT03574597
Trial comparisons16
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 16 of 16
Download this page as JSON| Comparison | Source |
|---|---|
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of Coronary Revascularisation | Trial comparisons |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of HF Requiring Hospitalisation or Urgent HF Visit | Trial comparisons |
| Semaglutide vs Placebo: Participants From Time of Randomisation to HbA1c ≥ 39 mmol/Mol (5.7%) (for Participants With a Screening HbA1c <39 mmol/Mol [5.7%]) | Trial comparisons |
Semaglutide vs Placebo: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke | Trial comparisons |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of Non-fatal Stroke | Trial comparisons |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of a Composite Outcome Measure Consisting of: All-cause Death, Non-fatal MI, or Non-fatal Stroke | Trial comparisons |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of a 5-component Composite Nephropathy Outcome Measure | Trial comparisons |
| Semaglutide vs Placebo: Participants From Time of Randomisation to CV Death | Trial comparisons |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of UAP Requiring Hospitalisation | Trial comparisons |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of Non-fatal MI | Trial comparisons |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of Glycosylated Haemoglobin (HbA1c) Greater Than Equals to (≥) 48 Millimole Per Mole (mmol/Mol) (6.5 Percentage [%]) | Trial comparisons |
Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of an Expanded Composite CV Outcome Measure Consisting of: CV Death, Non-fatal MI, Non-fatal Stroke, Coronary Revascularisation or Unstable Angina Pectoris (UAP) Requiring Hospitalisation | Trial comparisons |
| Semaglutide vs Placebo: deaths from any cause | Trial comparisons |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of a Composite Heart Failure (HF) Outcome Measure Consisting of: HF Hospitalisation, Urgent HF Visit or CV Death | Trial comparisons |
| Semaglutide vs Placebo: Participants From Time of Randomisation to All-cause Death | Trial comparisons |
| Semaglutide vs Placebo: serious adverse events | Trial comparisons |
trials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03574597/comparisons